Skip to main content
SpringerLink
Log in

Nose

  • Chapter
Practical Pharmaceutics

  • 7708 Accesses

Abstract

This chapter deals with preparations for nasal administration, with a local or a systemic effect. Classical nasal preparations were always associated with local ailments, but nowadays the interest in the nasal route for systemically acting substances and direct nose to brain delivery is increasing. Fast absorption, the possibility of high blood levels and a patient friendly dosage form are the reasons. Nasal administration of medicines with local effect is the first choice for the treatment of topical nasal disorders. It is also an attractive route for low dose active substances with a systemic effect, such as peptides or benzodiazepines (e.g. midazolam). When compared to parenteral administration nasal administration is more easily applied and causes less risk of infection.

Nasal preparations can be formulated as liquid, semi-solid or solid preparations and can contain one or more active substances. Whether intended for local or systemic action, the mucociliary function of the nose should be disturbed as little as possible by the preparation However, it is well known that active substances as well as excipients may have a negative influence on the mucociliary clearance, in other words may be ciliotoxic. In the formulation of nasal preparations one should take into consideration the possible damage to the cilia in relation to the indication and the period of use.

Within this chapter the emphasis is on dosage forms that are prepared in the pharmacy and on forms that are supplied by the pharmacy.

Based upon the chapter Neus by Annick Ludwig and Suzy Dreijer in the 2009 edition of Recepteerkunde.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hochhaus G, Sahasranaman S, Derendorf H, Möllmann H (2002) Intranasal glucocorticoid delivery: competition between local and systemic effects. STP Pharma Sci 12:23–31

    CAS  Google Scholar 

  2. Natriumchlorid-Natriumwasserstofcarbonat-Salzmischung. NRF 4.11 2. Fassung 2006. In: Neues Rezeptur-Formularium (NRF). Eschborn (D): Govi-Verlag Pharmazeutischer Verlag GmbH

    Google Scholar 

  3. Behl CR, Pimplaskar HK, Sileno AP, deMeireles J, Romeo VD (1998) Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 29:89–116

    Article  CAS  PubMed  Google Scholar 

  4. Al-Ghananeem AM, Sandefer EP, Doll WJ, Page RC, Chang Y, Digenis GA (2008) Gamma scintigraphy for testing bioequivalence: a case study on two cromolyn sodium nasal spray preparations. Int J Pharm 357:70–76

    Article  CAS  PubMed  Google Scholar 

  5. Newman SP, Pitcairn GR, Dalby RN (2004) Drug delivery to the nasal cavity: in vitro and in vivo assessment. Crit Rev Ther Drug Carrier Syst 21:21–66

    Article  PubMed  Google Scholar 

  6. Kublik H, Vidgren MT (1998) Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 29:157–177

    Article  CAS  PubMed  Google Scholar 

  7. Segers P, Speekenbrink RGH, Ubbink DT, van Ogtrop ML, van Mol BAMJ (2006) Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 296:2460–2466

    Article  CAS  PubMed  Google Scholar 

  8. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24

    Article  CAS  PubMed  Google Scholar 

  9. Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64:614–628

    Article  CAS  PubMed  Google Scholar 

  10. Ludwig A (1988) Neusdruppels. Farm Tijdschr Belg 60:357–373

    Google Scholar 

  11. Ugwoke MI, Verbeke N, Kinget R (2001) The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 53:3–22

    Article  CAS  PubMed  Google Scholar 

  12. Martin E, Schipper NGM, Verhoef JC, Merkus FWHM (1998) Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 29:13–38

    Article  Google Scholar 

  13. Ugwoke MI, Agu RU, Verbeke N, Kinget R (2005) Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 57:1640–1665

    Article  CAS  PubMed  Google Scholar 

  14. Guyton AC, Hall JE (2010) Textbook of medical physiology. Elsevier Health, Oxford, UK

    Google Scholar 

  15. Mygind N, Dahl R (1998) Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 29:3–12

    Article  CAS  PubMed  Google Scholar 

  16. Ugwoke MI, Agu RU, Jorissen M, Augustyns P, Sciot R, Verbeke N, Kinget R (2000) Nasal toxicological investigations of Carbopol 971P formulation of apomorfine: effects on ciliary beat frequency of human nasal primary cell culture and in vivo on rabbit nasal mucosa. Eur J Pharm Sci 9:387–396

    Article  CAS  PubMed  Google Scholar 

  17. Ugwoke MI, Agu RU, Jorissen M, Augustyns P, Sciot R, Verbeke N, Kinget R (2000) Toxicological investigations of the effects of carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa. Int J Pharm 205:43–51

    Article  CAS  PubMed  Google Scholar 

  18. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L (1999) Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178:55–65

    Article  CAS  PubMed  Google Scholar 

  19. Li L, Mathias NR, Heran CL, Moench P, Wall DA, Smith RL (2006) Carbopol-mediated paracellular transport enhancement in Calu-3 cell layers. J Pharm Sci 95:326–335

    Article  CAS  PubMed  Google Scholar 

  20. Lee VH, Yamamoto A, Kompella UB (1991) Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst 8:91–192

    CAS  PubMed  Google Scholar 

  21. Zaki NM, Awad GA, Mortada ND, AbdElHady SS (2007) Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci 32:296–307

    Article  CAS  PubMed  Google Scholar 

  22. Illum L (2012) Nasal drug delivery-recent developments and future prospects. J Control Release 161:254–263

    Article  CAS  PubMed  Google Scholar 

  23. Gudmundsdottir H, Sigurjonsdottir JF, Masson M, Fjalldal O, Stefansson E, Loftsson T (2001) Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie 56:963–966

    CAS  PubMed  Google Scholar 

  24. Marttin E, Verhoef JC, Romeijn SG, Zwart P, Merkus FWHM (1996) Acute histopathological effects of benzalkonium chloride and absorption enhancers on rat nasal epithelium in vivo. Int J Pharm 141:151–160

    Article  CAS  Google Scholar 

  25. Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PHM, Hermens WAJJ, Schipper NGM (1999) Cyclodextrins in nasal delivery. Adv Drug Deliv Rev 36:41–57

    Article  CAS  PubMed  Google Scholar 

  26. Asai K, Morishita M, Katsuta H, Hosoda S, Shinomiya Knoro M, Nagai T, Takayama K (2002) The effects of water-soluble cyclodextrines on the histological integrity of the rat nasal mucosa. Int J Pharm 246:25–35

    Article  CAS  PubMed  Google Scholar 

  27. Haffejee N, Du Plessis J, Müller DG, Schultz C, Kotzé AF, Goosen C (2001) Intranasal toxicity of selected absorption enhancers. Pharmazie 5:882–888

    Google Scholar 

  28. Zaki NM, Mortada ND, Awad GAS, AbdElHady SS (2006) Rapid-onset intranasal delivery of metoclopramide hydrochoride part II: safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm 327:97–103

    Article  CAS  PubMed  Google Scholar 

  29. Watts P, Smith A (2009) PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 6(5):543–552. doi:10.1517/17425240902939135

    Article  CAS  PubMed  Google Scholar 

  30. Schipper NGM, Verhoef JC, Merkus WHM (1991) The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 8:807–814

    Article  CAS  PubMed  Google Scholar 

  31. Mallants R, Jorissen M, Augustijns P (2007) Effect of preservatives on ciliary beat frequency in human nasal epithelial cell culture: single versus multiple exposure. Int J Pharm 338:64–69

    Article  CAS  PubMed  Google Scholar 

  32. Van de Donk HJM (1982) Nasal medication and ciliary movement. Rodopi, Amsterdam

    Google Scholar 

  33. Xylometazolineneusdruppels/ -neusspray 0,025% FNA. Jaar 2009. Formularium der Nederlandse Apothekers. Den Haag: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP)

    Google Scholar 

  34. www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2030795. Accessed 24 Nov 2013

  35. Knoester PD, Jonker DM, van der Hoeven RTM, Vermeij TAC, Edelbroek PM, de Haan GJ (2002) Midazolam intranasaal toegepast. Eventueel als noodmedicatie. Pharm Weekbl 137:112–117

    Google Scholar 

  36. Aurora J (2002) Development of nasal delivery systems: a review. Drug Deliv Technol 2:1–8

    Google Scholar 

  37. Washington N, Steele RJC, Jackson SJ, Bush D, Mason J, Gill DA et al (2000) Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm 198:139–146

    Article  CAS  PubMed  Google Scholar 

  38. Kibbe AH (2009) Benzalkonium chloride monograph. In: Rowe RC, Sheskey PJ, Quinn ME (eds) Handbook of pharmaceutical excipients, 6th edn. Pharmaceutical Press and American Pharmaceutical Association, London, p 57

    Google Scholar 

  39. Rieger MM (2009) Methylparaben monograph. In: Rowe RC, Sheskey PJ, Quinn ME (eds) Handbook of pharmaceutical excipients, 6th edn. Pharmaceutical Press and American Pharmaceutical Association, London, p 442

    Google Scholar 

  40. Viskose Natriumchlorid-Nasentropfen 0,9% NRF 8.3 (2006) Neues Rezeptur-Formularium. GOVI-Verlag Pharmazeutischer Verlag GMBH, Eschborn. Deutscher Apotheker-Verlag, Stuttgart

    Google Scholar 

  41. Lee CH, Moturi V, Lee Y (2009) Thixotropic property in pharmaceutical formulations. J Control Release 136:88–98

    Article  CAS  PubMed  Google Scholar 

  42. Sharpe SA, Sandweiss V, Tuazon J, Giordano M, Witchey-Lakshmanan L, Hart J, Sequeira J (2003) Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev Ind Pharm 29:1005–1012

    Article  CAS  PubMed  Google Scholar 

  43. Zitt M, Kosoglou T, Hubbell J (2007) Mometasonefuroate nasal spray: a review of safety and systemic effects. Drug Saf 30:317–326

    Article  CAS  PubMed  Google Scholar 

  44. Quraishi MS, Jones NS, Mason JDT (1997) The nasal delivery of drugs. Clinical Otolaryngol Allied Sci 22(4):289–301. doi:10.1046/j.1365-2273.1997.00019.x

    Article  CAS  Google Scholar 

  45. Jian L, Li Wan Po A (1993) Ciliotoxicity of methyl- and propyl-p-hydroxybenzoates: a dose response and surface response study. J Pharm Pharmacol 45:925–927

    Google Scholar 

  46. Marple B, Roland P, Benningr M (2004) Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg 130:131–141

    Article  PubMed  Google Scholar 

  47. Hodges NA, Denyer SP, Hanlon GW, Reynolds JP (1996) Preservative efficacy tests in formulated nasal products: reproducibility and factors affecting preservative activity. J Pharm Pharmacol 48:1237–1242

    Article  CAS  PubMed  Google Scholar 

  48. Menthol-Paraffinnasensalbe 0,6% NRF 8.9. Fassung 2006. Neues Rezeptur-Formularium. GOVI-Verlag Pharmazeutischer Verlag GMBH, Eschborn. Deutscher Apotheker-Verlag, Stuttgart

    Google Scholar 

  49. Hydroxyethylcellulosegel DAB. Deutsches Arzneibuch (DAB). Bonn: Deutscher Apotheker Verlag. Govi-Verlag Pharmazeutischer Verlag: Ergänzung 2010

    Google Scholar 

  50. NRF-rezepturhinweise: Nasensalben und Nasenemulsionen/www.pharmazeutische-zeitung.de/index.php?id=nrf_suche. Accessed Apr 2013

  51. Benzalkoniumbasisoplossing 0,1 mg/ml FNA. Jaar 2009. Formularium der Nederlandse Apothekers. Den Haag: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP)

    Google Scholar 

  52. Hypromellose-benzalkoniumoplossing FNA. Jaar 2009. Formularium der Nederlandse Apothekers. Den Haag: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP)

    Google Scholar 

  53. Merkus P, Ebbens FA, Muller B, Fokkens WJ (2006) The ‘best method’ of topical nasal drug delivery: comparison of seven techniques. Rhinology 44:102–107

    CAS  PubMed  Google Scholar 

  54. Pennington AK, Ratcliffe JH, Wilson CG, Hardy JG (1988) The influence of solution viscosity on nasal spray deposition and clearance. Int J Pharm 43:221–224

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Dutch Pharmacists’ Association KNMP, The Hague, The Netherlands

    Suzy Dreijer - van der Glas

  2. Department of Pharmaceutical Technology, University of Zagreb, Zagreb, Croatia

    Anita Hafner

Authors
  1. Suzy Dreijer - van der Glas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anita Hafner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anita Hafner .

Editor information

Editors and Affiliations

  1. Laboratory of Dutch Pharmacists, Royal Dutch Pharmacists Association KNMP, The Hague, The Netherlands

    Yvonne Bouwman-Boer

  2. Former Quality Control Pharmacist to the Welsh Hospitals, Cardiff, United Kingdom

    V'Iain Fenton-May

  3. The Hague Hospital Pharmacy, The Hague, The Netherlands

    Paul Le Brun

Rights and permissions

Reprints and permissions

Copyright information

© 2015 KNMP and Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dreijer - van der Glas, S., Hafner, A. (2015). Nose. In: Bouwman-Boer, Y., Fenton-May, V., Le Brun, P. (eds) Practical Pharmaceutics. Springer, Cham. https://doi.org/10.1007/978-3-319-15814-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-15814-3_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-15813-6

  • Online ISBN: 978-3-319-15814-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation